A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine

Marco Bartolini, Maria Adele Giamberardino, Carlo Lisotto, Paolo Martelletti, Davide Moscato, Biagio Panascia, Lidia Savi, Luigi Alberto Pini, Grazia Sances, Patrizia Santoro, Giorgio Zanchin, Stefano Omboni, Michel D. Ferrari, Filippo Brighina, Brigida Fierro

Research output: Contribution to journalArticle

Abstract

The objective of this study was to evaluate patients' satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1-3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting

Original languageEnglish
Pages (from-to)361-368
Number of pages8
JournalJournal of Headache and Pain
Volume12
Issue number3
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Migraine Disorders
Multicenter Studies
Migraine without Aura
Migraine with Aura
Patient Satisfaction
Cross-Over Studies
almotriptan
frovatriptan
Surveys and Questionnaires

Keywords

  • Almotriptan
  • Frovatriptan
  • Migraine
  • Patient preference

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology

Cite this

Bartolini, M., Giamberardino, M. A., Lisotto, C., Martelletti, P., Moscato, D., Panascia, B., ... Fierro, B. (2011). A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. Journal of Headache and Pain, 12(3), 361-368. https://doi.org/10.1007/s10194-011-0325-5

A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. / Bartolini, Marco; Giamberardino, Maria Adele; Lisotto, Carlo; Martelletti, Paolo; Moscato, Davide; Panascia, Biagio; Savi, Lidia; Pini, Luigi Alberto; Sances, Grazia; Santoro, Patrizia; Zanchin, Giorgio; Omboni, Stefano; Ferrari, Michel D.; Brighina, Filippo; Fierro, Brigida.

In: Journal of Headache and Pain, Vol. 12, No. 3, 06.2011, p. 361-368.

Research output: Contribution to journalArticle

Bartolini, M, Giamberardino, MA, Lisotto, C, Martelletti, P, Moscato, D, Panascia, B, Savi, L, Pini, LA, Sances, G, Santoro, P, Zanchin, G, Omboni, S, Ferrari, MD, Brighina, F & Fierro, B 2011, 'A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine', Journal of Headache and Pain, vol. 12, no. 3, pp. 361-368. https://doi.org/10.1007/s10194-011-0325-5
Bartolini, Marco ; Giamberardino, Maria Adele ; Lisotto, Carlo ; Martelletti, Paolo ; Moscato, Davide ; Panascia, Biagio ; Savi, Lidia ; Pini, Luigi Alberto ; Sances, Grazia ; Santoro, Patrizia ; Zanchin, Giorgio ; Omboni, Stefano ; Ferrari, Michel D. ; Brighina, Filippo ; Fierro, Brigida. / A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. In: Journal of Headache and Pain. 2011 ; Vol. 12, No. 3. pp. 361-368.
@article{4d4fe1ec33114f7f8bd3c5e6c1df2290,
title = "A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine",
abstract = "The objective of this study was to evaluate patients' satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1-3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting",
keywords = "Almotriptan, Frovatriptan, Migraine, Patient preference",
author = "Marco Bartolini and Giamberardino, {Maria Adele} and Carlo Lisotto and Paolo Martelletti and Davide Moscato and Biagio Panascia and Lidia Savi and Pini, {Luigi Alberto} and Grazia Sances and Patrizia Santoro and Giorgio Zanchin and Stefano Omboni and Ferrari, {Michel D.} and Filippo Brighina and Brigida Fierro",
year = "2011",
month = "6",
doi = "10.1007/s10194-011-0325-5",
language = "English",
volume = "12",
pages = "361--368",
journal = "Journal of Headache and Pain",
issn = "1129-2369",
publisher = "BioMed Central Ltd.",
number = "3",

}

TY - JOUR

T1 - A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine

AU - Bartolini, Marco

AU - Giamberardino, Maria Adele

AU - Lisotto, Carlo

AU - Martelletti, Paolo

AU - Moscato, Davide

AU - Panascia, Biagio

AU - Savi, Lidia

AU - Pini, Luigi Alberto

AU - Sances, Grazia

AU - Santoro, Patrizia

AU - Zanchin, Giorgio

AU - Omboni, Stefano

AU - Ferrari, Michel D.

AU - Brighina, Filippo

AU - Fierro, Brigida

PY - 2011/6

Y1 - 2011/6

N2 - The objective of this study was to evaluate patients' satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1-3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting

AB - The objective of this study was to evaluate patients' satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1-3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting

KW - Almotriptan

KW - Frovatriptan

KW - Migraine

KW - Patient preference

UR - http://www.scopus.com/inward/record.url?scp=79958139398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958139398&partnerID=8YFLogxK

U2 - 10.1007/s10194-011-0325-5

DO - 10.1007/s10194-011-0325-5

M3 - Article

C2 - 21437714

AN - SCOPUS:79958139398

VL - 12

SP - 361

EP - 368

JO - Journal of Headache and Pain

JF - Journal of Headache and Pain

SN - 1129-2369

IS - 3

ER -